期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

二甲双胍分别联合艾塞那肽及沙格列汀治疗2型糖尿病的疗效及安全性差异分析 被引量：3

下载PDF
导出
摘要 目的探讨二甲双胍分别联合艾塞那肽及沙格列汀治疗2型糖尿病(T2DM)的疗效和安全性的差异。方法选择该院2013年1月-2014年3月内分泌科诊治的T2DM患者118例,随机分为艾塞那肽组和沙格列汀组各59例,均联合二甲双胍治疗4个月后,比较2组糖化血红蛋白(HbA1c)、空腹血糖(FBG)、体质量指数(BMI)的变化以及不良反应发生情况。结果治疗后,艾塞那肽组HbA1c、FBG、BMI下降幅度均大于沙格列汀组,差异均有统计学意义(P<0.05),艾塞那肽组的不良反应主要以胃肠道反应为主,沙格列汀组患者主要表现为咳嗽、鼻塞和腹泻等反应。结论艾塞那肽和沙格列汀联合二甲双胍均可控制T2DM患者血糖水平,但艾塞那肽降糖作用更明显,尤其适合肥胖者,对于胃肠疾病患者,沙格列汀则更具有优势。
作者 郑玉卿 于永波 李要京 侯晓明 李强
机构地区 河北省曲阳县仁济医院
出处 《临床合理用药杂志》 2014年第25期123-124,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 糖尿病 2 型 二甲双胍 艾塞那肽 沙格列汀
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献5

二级参考文献25

  • 1Giugliano D, Standl E, Vilsboll T, et al. Is the current therapeutic ar- mamentarium in diabetes enough to control the epidemic and its conse- quences? What are the current shortcomings? [ J ]. Acta Diabetol, 2009, 46(3) : 173 -181.
  • 2Nauck M A. Unraveling the science of incretin biology [ J]. Eur J In- tern Med, 2009, 20( Suppl 2) : S303 -S308.
  • 3Gupta N A, Mells J, Dunham R M, et al. Glucagon-like peptide-I re- ceptor is present on human hepatocytes and has a direct role in decrea- sing hepatic steatosis in vitro by modulating elements of the insulin sig- naling pathway [J]. Hepatology, 2010, 51 (5): 1584- 1592.
  • 4Nathan D M, Buse J B, Davidson M B, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initia- tion and adjustment of therapy : a consensus statement of the American Diabetes Association and the European Association for the Study of Dia- betes [J]. Diabetes Care, 2009, 32( 1 ) : 193 -203.
  • 5Eng J, Kleinman W A, Singh L, et al. Isolation and characterization of exendin-.4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas I J]. J Biol Chem, 1992, 267( 11 ): 7402-7405.
  • 6Boulton D, Tang A, Patel C, et al. Pharmaeokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment [ J]. Endocr Abstr, 2009, 20: 357.
  • 7Yu Z, Jin T. New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 ( GLP-1 ) [ J].Cell Signal, 2010, 22(1) : 1 -8.
  • 8Fehse F, Trautmann M, Hoist J J, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes [ J]. J Clin Endocrinol Metab, 2005,90 (11) : 5991 -5997.
  • 9Buse J B, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes : a 26-week randomised, par- allel-group, multinational, open-label trial ( LEAD-6 ) [ J ]. Lancet, 2009, 374(9683): 39-47.
  • 10Erdogdu O, Nathanson D, Sjoholm A, et al. Exendin4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor[J]. Mol Cell Endocrinol, 2010, 325( 1/2): 26-35.

共引文献42

同被引文献45

  • 1UK Prospective Diabetes Study (UKPDS) Group. Intensive blood -glu- cose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes ( UK- PDS 33) [J]. Lancet,1998, 352(9131) :837 - 853.
  • 2Bouhon D,Tang A, Patel C, et al. Pharmacokinetics of the dipeptidyl peptidase -4 inhibitor saxagliptin in subjects with renal impairment[ J]. Endo Abstr,2009 ,20 :357.
  • 3Barnett A H, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add - on therapy in patients with poorly controlled type 2 diabetes on in- sulin alone or insulin combined with metformin[ J]. Curr Med Res Opin, 2012,28(4) :513 -523.
  • 4Green BD,Irwin N,Gault VA,et al. Development and ther-apeutic potential of incretin hormone analogues for type 2diabetes [J]. The British Journal of Diabetes and VascularDisease, 2005,5(3):134-140.
  • 5Tatosian DA,Guo Y,Schaeffer AK,et al. Dipeptidyl pep-tidase-4 inhibition in patients with type 2 diabetes treatedwith saxagliptin, sitagliptin, or vildagliptin[J]. Diabetes Ther-apy,2013,4(2) :431-442.
  • 6Defronzo RA,Hissa MN,Garber AJ,et al. The efficacy andsafety of saxagliptin when added to metformin therapy inpatients with inadequately controlled type 2 diabetes withmetformin alone[J]. Diabetes Care, 2009,32(9) : 1649-1655.
  • 7Goke B,Gallwitz B,Eriksson J,et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mel-litus inadequately controlled on metformin alone:A 52-week randomised controlled trial[J]. International Journalof Clinical Practice,2010,64(12): 1619-1631.
  • 8Chacra AR, Tan GH, Apanovitch A , et al. Saxagliptinadded to a submaximal dose of sulphonylurea improvesglycaemic control compared with uptitration of sulphony-lurea in patients with type 2 diabetes : A randomised con-trolled trial [J]. International Journal of Clinical Practice,2009,63(9):1395-1406.
  • 9钱芳,倪惠君.胰岛素和口服降糖药治疗糖尿病的临床应用[J].青岛医药卫生,2010,42(3):196-197. 被引量：4
  • 10蔡乐,刘萍.新型口服降糖药——二肽基肽酶-Ⅳ抑制剂[J].国际药学研究杂志,2010,37(5):361-365. 被引量：11

二级引证文献54

临床合理用药杂志
2014年 第25期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部